Targeting HER2 ( ERBB2 ) mutation-positive advanced biliary tractcancers with neratinib: Resultsfrom the phase II SUMMIT 'basket'trial

This article has no abstract
Epistemonikos ID: 4deb9c4317d20b1573a2d2bba1c9e16b3160bcd6
First added on: Feb 12, 2025